Dr. Keith D. Eaton is a medical oncologist at the Fred Hutchinson Cancer Center in Seattle, Washington, where he holds the titles of Clinical Director of Thoracic, Head, and Neck Medical Oncology, Medical Director for Quality, Safety, and Value, and is a professor in the Division of Hematology and Oncology at the University of Washington Medical Center. He specializes in treating patients with cancers of the lung, thyroid, head, and neck, as well as those diagnosed with cancer of unknown primary.
His patients include those diagnosed with lung cancer and malignant pleural mesothelioma, and he is committed to answering all of their questions honestly and educating them about their condition and available treatment protocols so that they can make informed decisions and participate fully in their own care. He is board-certified in Internal Medicine and Medical Oncology and is a member of the American Society of Clinical Oncology.
Dr. Eaton leads clinical trials investigating novel drug therapies and immunotherapy for the treatment of lung cancer. He is also working with medical colleagues to expand the understanding of cancer’s biology and to develop more targeted treatments.[1`]
His recent publications include:
- Impact of institutional interventions on the rate of paclitaxel hypersensitivity reactions. Mark Edward Jao, Amy Ly Indorf, Eve-Michelle Segal, Abby Miske, Keith David Eaton, Trisha Marsolini, Simran Ghuman>; Journal of Oncology Pharmacy Practice. 2024 Jan 1
- Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study. Melissa L Johnson, James Strauss, Manish R Patel, Edward B Garon, Keith D Eaton, Tavette Neskorik, Jos√©e Morin, Richard Chao, Balazs Halmos>; Clinical Lung Cancer. 2023 May 1
- Development of Neuropathic Arthropathy With Entrectinib: Case Report. Nicholas P Giustini, Hanna Oh, Keith D Eaton>; JTO Clinical and Research Reports. 2022 Nov 1
His active clinical trials include:
- Evaluation and Characterization of Small Cell Lung Cancer Using Circulating Tumor Cell Technology Evaluation and Characterization of Small Cell Lung Cancer Using Circulating Tumor Cell Technology. Trial phase: N/A
- Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation. Trial phase: I/II